查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974310

mRNA合成與製造市場：依服務、服務類型、製造流程、製造規模、技術、應用、使用方法及最終用戶分類－2026-2032年全球預測

mRNA Synthesis & Manufacturing Market by Services, Service Type, Manufacturing Process, Manufacturing Scale, Technology, Application, Usage, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，mRNA 合成和製造市場價值將達到 29.6 億美元，到 2026 年將成長到 32.3 億美元，到 2032 年將達到 56.7 億美元，複合年成長率為 9.71%。

主要市場統計數據
基準年 2025 29.6億美元
預計年份：2026年 32.3億美元
預測年份 2032 56.7億美元
複合年成長率 (%) 9.71%

作為權威的 mRNA 合成與生產入門教材，說明了科學基礎、商業化途徑、監管發展以及供應鏈的複雜性。

傳訊RNA的合成與生產融合了分子生物學、工程學、監管科學和全球供應鏈管理等多個學科，共同致力於開發新型治療方法和疫苗平台。其核心科學在於mRNA生產流程，該工藝透過一系列特定步驟，例如模板DNA製備、體外轉錄、加帽加尾、多聚腺苷酸化、純化和製劑化，將數位化基因設計轉化為化學和結構最佳化的RNA構建體。每個步驟都需要專門的試劑、設備和製程控制，這體現了RNA分子的精細結構以及確保產品品質對人類和動物使用至關重要的必要性。

定義變革性轉變，這將重塑 mRNA 的合成和生產，其驅動力包括平台技術、遞送方法創新、監管進步和策略夥伴關係。

由於技術成熟、策略聯盟的建立以及監管要求的改變，mRNA合成和生產領域正經歷變革時期。脂質奈米顆粒設計和新型遞送方式的進步，正在拓展mRNA療法的應用範圍，使其超越傳統疫苗，實現更精準的標靶遞送並提高耐受性。同時，酵素加帽化學、加帽類似物和多聚腺苷酸化技術的改進，正在提升轉錄物的穩定性和翻譯效率，進而提高mRNA構建體的治療指數。

檢驗美國於 2025 年實施的關稅對 mRNA 合成供應鏈、籌資策略、成本結構和競爭地位的累積影響。

美國2025年實施的關稅政策調整對整個mRNA合成價值鏈產生了多方面的影響，包括採購、成本結構和策略供應決策。某些試劑、特殊化學品和進口設備的關稅上調，增加了模板DNA製備、體外轉錄、酵素試劑和脂質賦形劑等關鍵投入品的總到岸成本。因此，採購團隊和供應鏈經理正在採取多元化策略，例如簽訂長期合約、採用第二供應商協議以及評估區域供應商，以降低關稅波動帶來的風險。

詳細的細分分析揭示了影響 mRNA 合成市場產品和需求的各項服務、流程、規模、技術、應用、用途和最終用戶趨勢。

透過嚴謹的市場細分，我們獲得了深刻的洞察，揭示了不同的價值促進因素，這些因素因服務、服務類型、製造程序、規模、技術、應用、使用場景和最終用戶群體而異，從而決定了mRNA合成能力的引入和商業化方式。按服務分類，市場活動主要集中在「加帽和加尾」、「In Silico設計」、「電腦輔助設計」、「修飾和最佳化」、「純化和品管」、「儲存和分發」以及「模板DNA製備」等領域，每個服務領域都需要專門的技能和品管系統。能夠以整合方式提供這些服務的供應商可以縮短開發週期，而擁有先進專業知識的細分領域專家則有可能獲得更高的利潤。

區域戰略觀點：重點關注美洲、歐洲、中東和非洲以及亞太地區的製造地、法規環境和貿易相互依存關係。

區域趨勢在美洲、歐洲、中東、非洲和亞太地區創造了不同的機會和營運考量，這些地區在創新能力、製造基礎設施、法規結構和貿易夥伴關係方面存在差異。在美洲，強大的轉化研究生態系統、豐富的創業投資和企業資本以及完善的合約研發生產機構（CDMO）網路，支持從概念到臨床試驗的快速進展。該地區還聚集了大量先進試劑供應商和專業分析服務提供商，為高品質生產提供支援。

關於主要企業、策略趨勢、能力差異化因素以及塑造 mRNA 合成和製造生態系統的夥伴關係行為的關鍵競爭見解。

mRNA合成領域的企業競爭呈現出平台專業化、垂直整合和協作模式相結合的特點，旨在平衡上市速度和資本密集度。該領域的領導企業正投資於整合In Silico設計工具與穩健的製程開發和製劑技術的平台，從而減少交接流程，縮短從藥物發現到符合GMP規範生產的周期。同時，其他企業則專注於先進脂質化學、高解析度純化技術和專有酶試劑等領域的細分市場，成為更廣泛生態系統中其他參與者的重要合作夥伴。

為產業領導者提供可操作的策略建議，以最佳化製造韌性、加快開發速度並增強全球供應鏈的敏捷性。

產業領導者應採取積極主動的措施，增強生產韌性，加快研發進程，並確保專案按計畫進行。首先，應實現關鍵材料（如酵素、脂質和質體材料）籌資策略的多元化，並確保檢驗的二級供應商，以減少單點故障。其次，應投資模組化和一次性製程技術，以提高中試、臨床和商業化生產宣傳活動的柔軟性，縮短切換時間並降低交叉污染的風險。第三，應優先加強先進的製劑和純化能力，包括脂質奈米顆粒技術和高解析度RNA純化技術的領先地位，以提高產品穩定性和臨床療效。

高度透明的調查方法，解釋了用於獲得關於 mRNA 合成的嚴格見解的數據來源、分析框架、專家檢驗和品管。

本分析所依據的研究採用了一種混合方法，結合了定性一手訪談、二手文獻綜述和技術檢驗，以確保結果的可靠性和實用性。主要資料來源是對產品開發和製造機構的製程開發科學家、供應鏈經理、法規事務專家和高階主管進行的結構化訪談。這些對話揭示了實際存在的限制、策略重點和切實可行的解決方案，並以此為基礎提出了可操作的建議。

經營團隊總結了策略見解、營運重點和前瞻性考慮因素，供 mRNA 合成和製造領域的相關人員參考。

總之，mRNA合成和生產正進入一個以技術快速進步、商業模式不斷演變以及對供應鏈韌性日益重視為特徵的階段。製劑技術、酵素學和數位設計方面的技術進步正在為提高治療效果鋪平道路，而不斷變化的監管要求則對分析精度和製程控制提出了更高的要求。貿易政策和區域趨勢的變化促使企業對採購和製造地進行策略性重新評估，使得供應鏈透明度和地域多角化成為營運策略的關鍵要素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 mRNA 合成與製造市場：依服務分類

  • 封頂和尾部
  • 配方
  • In Silico設計
  • 修改和最佳化
  • 精煉/品管
  • 倉儲/配送
  • 模板DNA製備

第9章 mRNA合成與製造市場：依服務類型分類

  • 客製化mRNA合成
    • 客戶客製的mRNA訂單
    • 客製化調查規範
  • 標準mRNA生產
    • 目錄中列出的mRNA變體
    • 選擇預製的mRNA

第10章 mRNA合成與製造市場：依製造流程分類

  • 先進的LNP製劑技術
  • 酶促加帽及其類似物
  • 基因工程和密碼子最佳化
  • 體外移植
  • 質體DNA模板
  • 多聚腺苷酸化
  • RNA純化技術

第11章 依生產規模分類的mRNA合成與製造市場

  • 商業規模
  • 實驗室規模
  • 中試規模

第12章 mRNA 合成與製造市場：依技術分類

  • 體外合成
  • 內源性合成

第13章 mRNA合成與製造市場：依應用領域分類

  • 治療藥物
    • 癌症
    • 感染疾病
    • 罕見疾病
  • 疫苗
    • 預防性疫苗
    • 治療性疫苗

第14章 mRNA合成與製造市場及其應用

  • 對人類而言
  • 獸用

第15章 mRNA 合成與製造市場：依最終用戶分類

  • 學術和研究機構
    • 政府研究機構
    • 大學研究所
  • 契約製造組織
  • 製藥和生物技術公司

第16章 mRNA 合成與製造市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 mRNA 合成與製造市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 mRNA 合成與製造市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 美國mRNA合成與製造市場

第20章 中國mRNA合成與製造市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
  • Bio-Synthesis Inc.
  • Creative Biogene
  • Creative Biolabs
  • Croyez Bioscience Co., Ltd.
  • Danaher Corporation
  • FUJIFILM Wako Pure Chemical Corporation
  • Genewiz by Azenta Life Sciences
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH by Enzo Biochem Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • New England Biolabs, Inc.
  • PackGene Biotech, Inc.
  • Promega Corporation
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • ST Pharm
  • System Biosciences, LLC
  • Takara Bio Inc.
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
  • WuXi Biologics（Cayman）Inc
Product Code: MRR-6067B28994B1

The mRNA Synthesis & Manufacturing Market was valued at USD 2.96 billion in 2025 and is projected to grow to USD 3.23 billion in 2026, with a CAGR of 9.71%, reaching USD 5.67 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.96 billion
Estimated Year [2026] USD 3.23 billion
Forecast Year [2032] USD 5.67 billion
CAGR (%) 9.71%

An authoritative introduction to mRNA synthesis and manufacturing highlighting scientific foundations, commercialization pathways, regulatory advances, and supply chain complexities

Messenger RNA synthesis and manufacturing represent a convergence of molecular biology, engineering, regulatory science, and global supply chain management that together enable new therapeutic modalities and vaccine platforms. At its scientific core, mRNA manufacturing translates digital genetic designs into chemically and structurally optimized RNA constructs through defined processes such as template DNA preparation, in vitro transcription, capping and tailing, polyadenylation, purification, and formulation. Each stage demands specialized reagents, instrumentation, and process controls that reflect both the sensitivity of RNA molecules and the criticality of ensuring product quality for human and veterinary use.

Beyond the bench, commercialization pathways require alignment between research organizations, contract manufacturers, regulatory authorities, and distribution networks. The ecosystem is characterized by a mix of academic research groups that drive discovery, specialty suppliers that provide enzymes and lipids, contract development and manufacturing organizations that enable scale-up, and biopharmaceutical firms that integrate mRNA into therapeutic pipelines. This interplay influences timelines, capital intensity, and risk allocation as programs move from proof-of-concept to clinical testing and, eventually, to broad deployment.

Regulatory and quality expectations are evolving in parallel with technical advances. Regulators are emphasizing robust characterization of critical quality attributes, consistency of production, and demonstrated control of process-related impurities. Consequently, manufacturers are investing in analytical platforms and quality assurance frameworks to meet stringent release criteria and to support global regulatory filings. At the same time, supply chain robustness, cold chain logistics, and secure sourcing of critical raw materials remain practical constraints that shape program feasibility and strategic decisions. Taken together, these dimensions set the stage for an industry focused on innovation, operational excellence, and careful regulatory engagement.

Defining transformative shifts reshaping mRNA synthesis and manufacturing driven by platform technologies, delivery innovations, regulatory evolution, and strategic partnerships

The landscape of mRNA synthesis and manufacturing is undergoing transformative shifts driven by technological maturation, strategic partnerships, and shifting regulatory expectations. Advances in lipid nanoparticle design and alternative delivery modalities are extending the reach of mRNA therapeutics beyond traditional vaccine applications, enabling targeted delivery and improved tolerability. Concurrent improvements in enzymatic capping chemistry, cap analogues, and polyadenylation methods are increasing transcript stability and translational efficiency, thereby improving the therapeutic index of mRNA constructs.

Digital tools and in silico design platforms are accelerating sequence optimization and codon engineering, reducing iterative laboratory cycles and enabling more predictive design-to-manufacture pathways. This digitization is complemented by automation from bench to production, where modular and single-use systems allow faster campaign changeovers and reduce cross-contamination risk. The growing prominence of contract manufacturing organizations and strategic alliances is shifting capital burdens and creating flexible capacity models that support both bespoke clinical-scale programs and larger commercial runs.

Regulatory convergence and clearer guidance on quality attributes are prompting manufacturers to embed quality-by-design principles earlier in development, ensuring scalable processes are validated before full-scale commercial production. In parallel, supply chain resilience has become a strategic dimension; organizations are diversifying supplier bases for critical inputs such as nucleotides, enzymes, and lipid excipients while exploring regional production strategies to mitigate trade and logistics disruptions. Together, these shifts are reshaping competitive dynamics and opening opportunities for firms that can integrate advanced formulation science, robust quality systems, and agile manufacturing models.

Examining the cumulative effects of United States tariffs implemented in 2025 on mRNA synthesis supply chains, sourcing strategies, cost structures, and competitive positioning

The 2025 adjustments to United States tariff policy have introduced layered effects across the mRNA synthesis value chain, influencing sourcing, cost structures, and strategic supply decisions. Tariff escalation on certain reagents, specialty chemicals, and imported equipment has increased the total landed cost of critical inputs used in template DNA preparation, in vitro transcription, enzymatic reagents, and lipid excipients. As a consequence, procurement teams and supply chain managers are evaluating long-term contracts, second-source arrangements, and regional suppliers to reduce exposure to tariff-driven variability.

Operationally, tariffs are accelerating conversations around nearshoring and onshoring of key manufacturing activities. Organizations are assessing the trade-offs between higher local labor and infrastructure costs and the benefits of reduced border friction, faster lead times, and improved regulatory alignment. At the same time, manufacturers are revisiting inventory strategies and revising safety stock levels for high-risk components, balancing working capital impacts against the risk of production interruption.

Strategic responses also include renegotiation of supplier agreements to incorporate tariff sharing mechanisms, adoption of tariff classification optimization where appropriate, and investment in domestic capability for high-value intermediates. Furthermore, tariffs have catalyzed a renewed emphasis on supply chain transparency and traceability, prompting increased use of supplier audits and digital tools to monitor origin, movement, and compliance of raw materials. Collectively, these adaptations reflect how trade policy can materially influence operational resilience, supplier selection, and longer-term manufacturing footprints for complex biologics such as mRNA products.

In-depth segmentation insights revealing service, process, scale, technology, application, usage, and end-user dynamics that influence mRNA synthesis market offerings and demand

Insights derived from rigorous segmentation reveal distinct value drivers across services, service types, manufacturing processes, scales, technologies, applications, usage contexts, and end-user groups that define how mRNA synthesis capabilities are deployed and monetized. Based on Services, market activity clusters around Capping & Tailing, Formulation, In Silico Design, Modification & Optimization, Purification & Quality Control, Storage & Distribution, and Template DNA Preparation, with each service area requiring specialized skill sets and quality regimes. Providers offering an integrated suite of these services can shorten development timelines, whereas niche specialists may command premium margins for advanced capabilities.

Based on Service Type, distinctions between Custom mRNA Synthesis and Standard mRNA Production are material for positioning and client engagement. Custom mRNA Synthesis, including Client-Specific mRNA Orders and Tailored Research Specifications, caters to bespoke therapeutic programs and academic discovery projects where flexibility and deep technical support are essential. Standard mRNA Production, composed of Cataloged mRNA Variants and Off-the-Shelf mRNA Selections, aligns with reagent suppliers and platform offerings that prioritize reproducibility and immediate availability for screening or adjunct research applications.

Based on Manufacturing Process, competitive differentiation often stems from leadership in Advanced LNP Formulation Technology, Enzymatic Capping & Cap Analogues, Genetic Engineering & Codon Optimization, In Vitro Transcription, Plasmid DNA Template work, Polyadenylation, and RNA Purification Techniques. Mastery across these process elements reduces downstream risk and can accelerate clinical readiness. Based on Manufacturing Scale, providers operating across Commercial Scale, Lab Scale, and Pilot Scale can capture opportunity across development stages, but must maintain process transfer discipline to ensure performance parity when scaling.

Based on Technology, the split between In Vitro Synthesis and In Vivo Synthesis informs platform investments and regulatory approaches, with each route presenting unique quality and delivery considerations. Based on Application, differentiation emerges between Therapeutics and Vaccines, where Therapeutics encompasses Cancer, Infectious Diseases, and Rare Diseases and Vaccines comprises Prophylactic and Therapeutic Vaccines, each application area carrying distinct development timelines, clinical endpoints, and payer considerations. Based on Usage, Human Use and Veterinary Use markets require tailored regulatory pathways and manufacturing controls. Based on End-User, Academic & Research Institutes, Contract Manufacturing Organizations, and Pharmaceutical & Biotechnology Companies represent primary demand pockets, with Academic & Research Institutes further segmented into Government Research Bodies and University Laboratories, reflecting divergent procurement behaviors and quality expectations. Together, these segmentation lenses enable clearer targeting of capabilities, investment priorities, and commercial propositions for providers across the mRNA ecosystem.

Regional strategic perspectives across the Americas, Europe Middle East & Africa, and Asia-Pacific highlighting manufacturing hubs, regulatory climates, and trade interdependencies

Regional dynamics create differentiated opportunities and operational considerations across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each presenting distinct balances of innovation capacity, manufacturing infrastructure, regulatory frameworks, and trade linkages. In the Americas, strong translational research ecosystems, deep venture and corporate capital availability, and a robust network of contract development and manufacturing organizations support accelerated progression from concept to clinic. This region also benefits from a concentration of advanced reagent suppliers and specialized analytics providers that underpin high-quality production.

In Europe, Middle East & Africa, established pharmaceutical clusters, experienced regulatory bodies, and a tradition of collaboration between public research institutions and industry create an environment conducive to complex biologics development and cross-border partnerships. Regulatory harmonization efforts and a focus on manufacturing excellence make this region attractive for firms seeking high-standards production and access to diverse talent pools. The Asia-Pacific region combines large-scale manufacturing capabilities, growing R&D investment, and competitive operational cost structures. Rapid expansion of local supply chains, development of regional CDMOs, and governmental incentives for biotechnology investment are driving increased capacity for both development and commercial-scale manufacturing.

Across all regions, trade policies, logistics infrastructure, and workforce availability shape strategic decisions about where to locate specific manufacturing activities. Geopolitical considerations and tariff environments are prompting firms to consider hybrid and regionally diversified strategies to optimize responsiveness, regulatory alignment, and cost efficiency. Ultimately, a nuanced regional approach that aligns technical requirements with local strengths and policy realities will determine operational success in global mRNA supply networks.

Critical competitive intelligence on leading companies, strategic moves, capability differentiators, and partnership behaviors shaping mRNA synthesis and manufacturing ecosystems

Competitive behavior among companies operating in the mRNA synthesis sphere is characterized by a mix of platform specialization, vertical integration, and collaborative models that balance speed-to-market with capital intensity. Leaders in the field are investing in integrated platforms that combine in silico design tools with robust process development and formulation capabilities, thereby reducing handoffs and compressing timelines between discovery and GMP production. Other firms are concentrating on niche excellence, for example in advanced lipid chemistry, high-resolution purification technologies, or proprietary enzymatic reagents, thereby becoming critical partners for broader ecosystem participants.

Strategic moves commonly observed include technology licensing, co-development agreements, and alliances with specialized CDMOs to secure capacity and technical know-how. Mergers and acquisitions are being used selectively to acquire capability gaps quickly, while partnerships with academic centers support early access to novel sequences and translational insights. Investments in analytical development, process characterization, and digital manufacturing controls are differentiators that underpin regulatory filings and product consistency. Importantly, suppliers that can demonstrate validated supply chains for high-risk inputs and that offer contamination risk mitigation measures are increasingly preferred by developers who require secure sourcing for clinical and commercial programs.

Actionable strategic recommendations for industry leaders to optimize manufacturing resilience, accelerate development throughput, and strengthen global supply chain agility

Industry leaders should take a proactive stance to strengthen manufacturing resilience, accelerate development throughput, and protect program timelines. First, diversify sourcing strategies for critical inputs and establish validated second-source suppliers for enzymes, lipids, and plasmid materials to reduce single-point vulnerabilities. Second, invest in modular and single-use process technologies to increase flexibility across pilot, clinical, and commercial campaigns, enabling faster changeovers and lower cross-contamination risk. Third, prioritize advanced formulation and purification capabilities, including leadership in lipid nanoparticle engineering and high-resolution RNA purification, to improve product stability and clinical performance.

Additionally, embed quality-by-design practices earlier in development and expand analytical capabilities to support robust characterization and regulatory readiness. Strengthen partnerships with contract manufacturers and academic collaborators to access specialized expertise while managing capital exposure. Implement digital tools for in silico design, process analytics, and supply chain visibility to accelerate iteration cycles and to improve traceability. Finally, conduct scenario planning for trade and tariff changes, incorporating contractual hedges and regional manufacturing options to maintain continuity under shifting policy environments. These actions, taken together, will position organizations to respond more rapidly to scientific opportunities while mitigating operational and commercial risks.

Transparent research methodology explaining data sources, analytical frameworks, expert validation, and quality controls used to produce rigorous mRNA synthesis insights

The research underpinning this analysis employed a mixed-methods approach combining primary qualitative interviews, secondary literature review, and technical validation to ensure findings are robust and operationally relevant. Primary inputs included structured interviews with process development scientists, supply chain managers, regulatory affairs professionals, and senior executives across product developers and manufacturing organizations. These conversations were designed to elicit real-world constraints, strategic priorities, and practical mitigation tactics that inform actionable recommendations.

Secondary research included systematic review of peer-reviewed literature, publicly available regulatory guidance, patent filings, and technical white papers to map technology trajectories and identify validated process innovations. Where possible, triangulation methods were applied by cross-referencing interview insights with documented regulatory trends and supplier disclosures. Analytical frameworks focused on capability mapping, risk assessment, and scenario analysis, and findings were iteratively refined through an expert validation panel to reduce bias and strengthen applicability. Quality controls included source documentation, transparent assumption logs, and reproducible analytical steps to support traceability of conclusions.

Executive conclusion synthesizing strategic implications, operational priorities, and future-focused considerations for stakeholders in the mRNA synthesis and manufacturing domain

In conclusion, mRNA synthesis and manufacturing have entered a phase defined by rapid technical refinement, shifting commercial models, and heightened attention to supply chain resilience. Technological advances in formulation, enzymology, and digital design are creating pathways to broaden therapeutic impact, while evolving regulatory expectations are raising the bar for analytical rigor and process control. Trade policy shifts and regional dynamics are prompting strategic re-evaluation of sourcing and manufacturing footprints, making supply chain transparency and regional diversification essential components of operational strategy.

For stakeholders across the spectrum-developers, manufacturers, suppliers, and investors-the imperative is to align scientific ambition with pragmatic operational planning. Firms that integrate advanced process capabilities, adopt flexible manufacturing architectures, and engage in purposeful partnerships will be best positioned to translate mRNA innovation into dependable clinical and commercial outcomes. The emerging landscape rewards not just scientific ingenuity but also disciplined execution, strategic foresight, and resilient supply chain design.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. mRNA Synthesis & Manufacturing Market, by Services

  • 8.1. Capping & Tailing
  • 8.2. Formulation
  • 8.3. In Silico Design
  • 8.4. Modification & Optimization
  • 8.5. Purification & Quality Control
  • 8.6. Storage & Distribution
  • 8.7. Template DNA Preparation

9. mRNA Synthesis & Manufacturing Market, by Service Type

  • 9.1. Custom mRNA Synthesis
    • 9.1.1. Client-Specific mRNA Orders
    • 9.1.2. Tailored Research Specifications
  • 9.2. Standard mRNA Production
    • 9.2.1. Cataloged mRNA Variants
    • 9.2.2. Off-the-Shelf mRNA Selections

10. mRNA Synthesis & Manufacturing Market, by Manufacturing Process

  • 10.1. Advanced LNP Formulation Technology
  • 10.2. Enzymatic Capping & Cap Analogues
  • 10.3. Genetic Engineering & Codon Optimization
  • 10.4. In Vitro Transcription
  • 10.5. Plasmid DNA Template
  • 10.6. Polyadenylation
  • 10.7. RNA Purification Techniques

11. mRNA Synthesis & Manufacturing Market, by Manufacturing Scale

  • 11.1. Commercial Scale
  • 11.2. Lab Scale
  • 11.3. Pilot Scale

12. mRNA Synthesis & Manufacturing Market, by Technology

  • 12.1. In Vitro Synthesis
  • 12.2. In Vivo Synthesis

13. mRNA Synthesis & Manufacturing Market, by Application

  • 13.1. Therapeutics
    • 13.1.1. Cancer
    • 13.1.2. Infectious Diseases
    • 13.1.3. Rare Diseases
  • 13.2. Vaccines
    • 13.2.1. Prophylactic Vaccines
    • 13.2.2. Therapeutic Vaccines

14. mRNA Synthesis & Manufacturing Market, by Usage

  • 14.1. Human Use
  • 14.2. Veterinary Use

15. mRNA Synthesis & Manufacturing Market, by End-User

  • 15.1. Academic & Research Institutes
    • 15.1.1. Government Research Bodies
    • 15.1.2. University Laboratories
  • 15.2. Contract Manufacturing Organizations
  • 15.3. Pharmaceutical & Biotechnology Companies

16. mRNA Synthesis & Manufacturing Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. mRNA Synthesis & Manufacturing Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. mRNA Synthesis & Manufacturing Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States mRNA Synthesis & Manufacturing Market

20. China mRNA Synthesis & Manufacturing Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
  • 21.6. Bio-Synthesis Inc.
  • 21.7. Creative Biogene
  • 21.8. Creative Biolabs
  • 21.9. Croyez Bioscience Co., Ltd.
  • 21.10. Danaher Corporation
  • 21.11. FUJIFILM Wako Pure Chemical Corporation
  • 21.12. Genewiz by Azenta Life Sciences
  • 21.13. GenScript Biotech Corporation
  • 21.14. Jena Bioscience GmbH by Enzo Biochem Inc.
  • 21.15. Lonza Group Ltd.
  • 21.16. Merck KGaA
  • 21.17. New England Biolabs, Inc.
  • 21.18. PackGene Biotech, Inc.
  • 21.19. Promega Corporation
  • 21.20. Samsung Biologics Co., Ltd.
  • 21.21. Sartorius AG
  • 21.22. ST Pharm
  • 21.23. System Biosciences, LLC
  • 21.24. Takara Bio Inc.
  • 21.25. Telesis Bio Inc.
  • 21.26. Thermo Fisher Scientific Inc.
  • 21.27. TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
  • 21.28. WuXi Biologics (Cayman) Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 228. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 229. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 230. AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 257. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 260. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 261. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 262. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 264. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 265. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 266. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 267. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 269. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 270. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 271. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 272. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 273. GCC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPEAN UNION MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-US